Brokerages Expect Voyager Therapeutics Inc (NASDAQ:VYGR) Will Post Earnings of -$0.87 Per Share

Wall Street brokerages expect Voyager Therapeutics Inc (NASDAQ:VYGR) to announce ($0.87) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Voyager Therapeutics’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.69). Voyager Therapeutics posted earnings of ($0.63) per share during the same quarter last year, which indicates a negative year over year growth rate of 38.1%. The business is scheduled to announce its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Voyager Therapeutics will report full-year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($3.92) to ($1.29). For the next year, analysts anticipate that the firm will post earnings of ($2.68) per share, with EPS estimates ranging from ($4.99) to ($1.37). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Friday, August 9th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $1.17. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The firm had revenue of $46.09 million for the quarter, compared to analysts’ expectations of $5.25 million.

Several analysts have issued reports on the company. BidaskClub cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $26.00 target price on shares of Voyager Therapeutics in a report on Monday, August 12th. Morgan Stanley upped their target price on Voyager Therapeutics from $21.00 to $28.00 and gave the company an “equal weight” rating in a report on Friday, July 12th. Nomura reaffirmed a “buy” rating and set a $37.00 target price on shares of Voyager Therapeutics in a report on Tuesday, August 13th. Finally, Wedbush upped their target price on Voyager Therapeutics from $27.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $27.50.

Large investors have recently bought and sold shares of the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Voyager Therapeutics by 15.8% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 13,174 shares of the company’s stock worth $252,000 after buying an additional 1,794 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Voyager Therapeutics by 1.0% in the 1st quarter. Acadian Asset Management LLC now owns 46,500 shares of the company’s stock worth $890,000 after buying an additional 469 shares in the last quarter. Spark Investment Management LLC grew its holdings in Voyager Therapeutics by 18.5% in the 1st quarter. Spark Investment Management LLC now owns 146,200 shares of the company’s stock worth $2,798,000 after buying an additional 22,800 shares in the last quarter. Bank of America Corp DE grew its holdings in Voyager Therapeutics by 211.0% in the 4th quarter. Bank of America Corp DE now owns 10,637 shares of the company’s stock worth $100,000 after buying an additional 7,217 shares in the last quarter. Finally, Bailard Inc. bought a new position in Voyager Therapeutics in the 2nd quarter worth approximately $1,116,000. 75.39% of the stock is owned by institutional investors.

NASDAQ VYGR traded down $0.83 on Monday, hitting $19.65. 337,108 shares of the stock traded hands, compared to its average volume of 389,768. The stock has a 50-day moving average of $22.99 and a 200 day moving average of $20.89. Voyager Therapeutics has a twelve month low of $7.76 and a twelve month high of $28.79. The company has a market capitalization of $782.26 million, a P/E ratio of -7.15 and a beta of 2.55.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Read More: The primary rules of Elliott Wave theory

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.